{"version":"1.0","type":"rich","provider_name":"techandbusiness.org","provider_url":"https://techandbusiness.org","title":"Ultragenyx plans staff cuts and ends Wilson disease gene therapy development","author_name":"techandbusiness.org · Tech & Business","thumbnail_url":"https://cdn.thepharmaletter.com/convert/files/2024/06/4e5bab90-21c1-11ef-b9fd-3d6df514ffbd-logo-ultragenyx-copro.png/r%5Bwidth%5D=1280/4e5bab90-21c1-11ef-b9fd-3d6df514ffbd-logo-ultragenyx-copro.png","width":600,"height":400,"html":"<blockquote class=\"tb-newswire-embed\" style=\"max-width:600px;border-left:3px solid #22d3ee;padding:12px 16px;margin:0;font-family:-apple-system,system-ui,sans-serif;background:#09090b;border-radius:0 8px 8px 0;\">\n      <p style=\"margin:0 0 8px;font-size:10px;font-weight:600;letter-spacing:0.1em;color:#71717a;\">techandbusiness.org · Tech & Business</p>\n      <p style=\"margin:0 0 8px;font-size:18px;font-weight:700;line-height:1.3;color:#fff;\"><a href=\"https://techandbusiness.org/newswire/GE74zfz1ARrEvuUofRWeLZ\" style=\"color:#fff;text-decoration:none;\">Ultragenyx plans staff cuts and ends Wilson disease gene therapy development</a></p>\n      <p style=\"margin:0;font-size:14px;color:#a1a1aa;line-height:1.5;\">Ultragenyx plans to cut headcount by about 20%, to roughly 1,000 employees, and terminate development of UX701, its gene therapy for Wilson disease, The Pharma Letter reported.</p>\n    </blockquote>"}